We are delighted to share that our company has been selected to receive a grant from the Austrian Lifesciences Programme, a prestigious initiative administered by the Austrian Research Promotion Agency. This grant is a testament to the innovative work we are doing in the field of life sciences and will help us to continue pushing the boundaries of scientific research and development. With the support of the Austrian Life Sciences Programme, we can accelerate our efforts on our ground-breaking ideas.
Our Presentation at EuroPCR 2023
We are excited to announce that our company will not only participate in EuroPCR 2023, but we will also be giving a presentation at the conference! This is a fantastic opportunity for us to showcase our latest research and innovation.
EuroPCR is one of the largest and most prestigious conferences in the field of cardiology, and we are honored to be a part of it.
We invite you to join us at EuroPCR 2023 to learn more about our innovative implant and hear our presentation.
Presentation at Transcatheter Cardiovascular Therapeutics (TCT) Conference in Boston
We are excited to announce that AVVie will be attending TCT 2022 Boston.
The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation’s (CRF) annual scientific symposium. The world’s foremost educational forum specializing in interventional cardiovascular medicine will be held on September 16-19, 2022, at Boston Convention and Exhibition Center.
Dr. Mathew R. Williams will present our technology and latest achievements on September 18th in TCT Innovation: Transcatheter Mitral Valve Technologies session.
AVVie Awarded EU Seal of Excellence
AVVie was recently given the Seal of Excellence by the European Commission, a prestigious recognition for superior, innovative concepts deserving financial support. With this award, the European Commission affirms AVVie as a highly innovative company that can successfully compete globally in fast-growing areas.
The Seal of Excellence is a high-quality certificate given to projects submitted to the Horizon Program that have met all the strict selection and award requirements but were unable to get funding because of budgetary restrictions. The „Seal“ proves that the AVVie has commercial value and justifies support from different sources, whether public, private, national, regional, European, or global.
For more information about the Seal of Excellence, visit www.ec.europe.eu
Grand opening of our new lab space
On May 5th, we opened a new lab for isolated perfused hearts. We are now able to implant our mitral valve repair devices in isolated animal and human hearts, showing the function of our implants. Direct endoscopic vision allows to monitor the deployment process and will guide interventionists for the training of clinical applications.The new facility extends the analysis of our AVVie repair systems. In addition, the AVVie integrated test facility can help enhance usability and mitigate use errors through repetitive usage of handling devices during the implantation process.
AVVie awarded second place in the MedTech Virtual Tech Pitch competition.
AVVie was awarded second place in the MedTech Virtual Tech Pitch competition, that was held on August 17. The competition was organised by state government office in Minnesota in partnership with Medical Alley Association, Launch Minnesota and SelectUSA.
Department of Employment and Economic Development (DEED) announced winners for foreign-owned Medical Technology (MedTech) companies 2 days later.
Out of the 32 MedTech companies from 13 different countries 5 finalists were selected and the 3 winners will have the opportunity to connect directly with a group of Minnesota based startup support programs.
AVVie GmbH (‘Angel Valve’) achieved important milestone
Mitral Butterfly is a proprietary chordal repair technique restoring the coaptation plane of a flail leaflet in degenerative mitral regurgitation. Additionally, the unique deployment technique restores the support apparatus of the mitral valve in one step. It is an unparalleled technique and a differentiated method from presently known repair concepts. The primary advantage of the mechanism of action containing the prolapsing segment is the introduction of an artificial papillary muscle as valvular support.
The Mitral Butterfly device is intended to advance chordal repair. The present chronic animal study was to demonstrate safety of the device at 90-day follow-up. There were no device related adverse effects and no deterioration of valve function during follow up. All safety endpoints were met, and structural integrity was maintained out to an average of 12 million cycles per animal.
Patrick Maguire MD, MBA, said: “the successful completion of the chronic animal study is a major step in the development of a feasible mitral repair system and an advancement of mitral innovation”. Werner Mohl, MD, PhD, Founder of AVVie added: “we are pleased to reach this important milestone in line with our ambitious development plan. We are committed to bring a safe and effective device to the clinical arena.
AVVie wins BoB Award 2019
AVVie GmbH has been announced as the start-up track winner in the category MedTech in the Best of Biotech (BoB) 2019 Ceremony Awards.
BoB – Best of Biotech is an international life science businessplan competition recognizing life science innovations and honoring scientists. The BoB award program gives innovators a chance to stand out in the life science community and motivates them to become entrepreneurs. The aim of BoB is to promote Austria and Central Europe as a life science business incubator, active in the pharmaceutical, biotech and medtech fields.
On 23rd of October 2019 the Austrian Federal Ministry for Digital and Economic Affairs and Austria Wirtschaftsservice announced the award winners at the aws Bob – Best of Biotech: Award Ceremony (httpss://www.bestofbiotech.at/winners/), the prestigious gathering of the best early phase pitches and the best start up projects in each of the following categories: biotech/pharma, medtech and digital health. Finalists were selected by a group of experienced judges and, from the group of finalists, one winner from each category was awarded.
AVVie GmbH was announced as the winner of the first edition of Innovasc organized by iVascular. iVascular is a company dedicated to the development, commercialization and manufacture of technologically advanced medical devices and treatment methods for different vascular diseases.
For more information see:
Mitral Butterfly at the TVT Structural Heart Summit
“Mitral Butterfly” will be presented in one of the most prestigious meetings for structural heart innovations worldwide.
Moreover, the abstract „Mitral Butterfly: Evaluation of a novel device in porcine and human hearts“ has been accepted and will be presented at the TVT Moderated Poster Session.
It is a great scientific success and a unique opportunity to be a part of such a clinically-relevant conference in structural heart disease.
It is an honour to be actively involved in the innovation session of the TVT Structural Heart Summit in Chicago this year.